DE60128070D1 - Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors - Google Patents
Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumorsInfo
- Publication number
- DE60128070D1 DE60128070D1 DE60128070T DE60128070T DE60128070D1 DE 60128070 D1 DE60128070 D1 DE 60128070D1 DE 60128070 T DE60128070 T DE 60128070T DE 60128070 T DE60128070 T DE 60128070T DE 60128070 D1 DE60128070 D1 DE 60128070D1
- Authority
- DE
- Germany
- Prior art keywords
- kidney
- antigen
- dumper
- nursed
- vaccinated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18242900P | 2000-02-14 | 2000-02-14 | |
US182429P | 2000-02-14 | ||
US18263600P | 2000-02-15 | 2000-02-15 | |
US182636P | 2000-02-15 | ||
PCT/US2001/004595 WO2001060317A2 (en) | 2000-02-14 | 2001-02-13 | Kidney-specific tumor vaccine directed against kidney tumor antigen g-250 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60128070D1 true DE60128070D1 (de) | 2007-06-06 |
DE60128070T2 DE60128070T2 (de) | 2008-01-10 |
Family
ID=26878083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60128070T Expired - Lifetime DE60128070T2 (de) | 2000-02-14 | 2001-02-13 | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors |
Country Status (7)
Country | Link |
---|---|
US (5) | US7572891B2 (de) |
EP (1) | EP1255554B1 (de) |
AT (1) | ATE360430T1 (de) |
AU (1) | AU2001236967A1 (de) |
DE (1) | DE60128070T2 (de) |
ES (1) | ES2286104T3 (de) |
WO (1) | WO2001060317A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187307B1 (en) * | 1997-01-31 | 2001-02-13 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
US7572891B2 (en) | 2000-02-14 | 2009-08-11 | The Regents Of The University Of California | Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 |
US6646209B2 (en) * | 2001-04-13 | 2003-11-11 | Pelstar, L.L.C. | Beam scale with user friendly features |
WO2003089659A1 (en) * | 2002-04-16 | 2003-10-30 | The Regents Of The University Of California | Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix |
WO2004067029A1 (fr) * | 2002-12-27 | 2004-08-12 | Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. | Procede de preparation d'un vaccin et vaccins antitumoraux |
CN1548537B (zh) * | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
US20090214494A1 (en) * | 2005-03-29 | 2009-08-27 | The Board Of Trustees Of The University Of Illinoi | Cancer Vaccines and Therapeutic Methods |
EP1934250A2 (de) * | 2005-09-09 | 2008-06-25 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Verfahren und zusammensetzungen zur zelltodhemmung und verstärkung der zellproliferation |
KR100825984B1 (ko) * | 2006-03-24 | 2008-04-28 | 가톨릭대학교 산학협력단 | 조사된 인간 b형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물 |
WO2007134325A2 (en) * | 2006-05-15 | 2007-11-22 | Introgen Therapeutics, Inc. | Methods and compositions for protein production using adenoviral vectors |
WO2008080112A2 (en) | 2006-12-22 | 2008-07-03 | The Regents Of The University Of California | New fusion molecule based on novel taa variant |
US20160058856A1 (en) * | 2013-04-05 | 2016-03-03 | Kyushu University, National University Corporation | Anti-tumor dna vaccine |
EP3579870A4 (de) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
KR20190134631A (ko) | 2017-03-01 | 2019-12-04 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972353A (en) * | 1992-03-11 | 1999-10-26 | Institute Of Virology, Slovak Academy Of Sciences | MN proteins, polypeptides, fusion proteins and fusion polypeptides |
CA2192678C (en) | 1994-06-15 | 2010-12-14 | Jan Zavada | Mn gene and protein |
NZ289721A (en) * | 1994-07-07 | 1997-11-24 | Immunex Corp | Fusion proteins comprising gm-csf and antigens; their expression on yeast |
US7250291B1 (en) * | 1998-08-07 | 2007-07-31 | Dana-Farber Cancer Institute | Tumor antigens and uses thereof |
US7572891B2 (en) | 2000-02-14 | 2009-08-11 | The Regents Of The University Of California | Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 |
EP1673630A4 (de) | 2003-10-16 | 2009-04-29 | Inst Virology | Mn/ca ix und krebsprognose |
JP5653299B2 (ja) | 2011-06-09 | 2015-01-14 | 株式会社ジャパンディスプレイ | 液晶表示装置 |
-
2001
- 2001-02-13 US US09/783,708 patent/US7572891B2/en not_active Expired - Lifetime
- 2001-02-13 AT AT01909186T patent/ATE360430T1/de not_active IP Right Cessation
- 2001-02-13 AU AU2001236967A patent/AU2001236967A1/en not_active Abandoned
- 2001-02-13 DE DE60128070T patent/DE60128070T2/de not_active Expired - Lifetime
- 2001-02-13 WO PCT/US2001/004595 patent/WO2001060317A2/en active IP Right Grant
- 2001-02-13 EP EP01909186A patent/EP1255554B1/de not_active Expired - Lifetime
- 2001-02-13 ES ES01909186T patent/ES2286104T3/es not_active Expired - Lifetime
-
2009
- 2009-06-05 US US12/479,415 patent/US8741306B2/en not_active Expired - Fee Related
-
2014
- 2014-05-02 US US14/268,662 patent/US9409965B2/en not_active Expired - Lifetime
-
2016
- 2016-07-01 US US15/200,885 patent/US10035981B2/en not_active Expired - Fee Related
-
2018
- 2018-06-27 US US16/020,565 patent/US20180371411A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180371411A1 (en) | 2018-12-27 |
US9409965B2 (en) | 2016-08-09 |
US20100129313A1 (en) | 2010-05-27 |
US10035981B2 (en) | 2018-07-31 |
DE60128070T2 (de) | 2008-01-10 |
EP1255554A2 (de) | 2002-11-13 |
EP1255554A4 (de) | 2004-12-08 |
US7572891B2 (en) | 2009-08-11 |
WO2001060317A3 (en) | 2002-05-02 |
US20150010587A1 (en) | 2015-01-08 |
WO2001060317A2 (en) | 2001-08-23 |
US20020058041A1 (en) | 2002-05-16 |
US20160376556A1 (en) | 2016-12-29 |
ES2286104T3 (es) | 2007-12-01 |
EP1255554B1 (de) | 2007-04-25 |
ATE360430T1 (de) | 2007-05-15 |
AU2001236967A1 (en) | 2001-08-27 |
US8741306B2 (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60128070D1 (de) | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors | |
Warren et al. | Uses of granulocyte-macrophage colony-stimulating factor in vaccine development | |
Rosenberg | Progress in human tumour immunology and immunotherapy | |
Berzofsky et al. | Progress on new vaccine strategies for the immunotherapy and prevention of cancer | |
Rosenberg et al. | Cancer immunotherapy: moving beyond current vaccines | |
Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
Oosterwijk-Wakka et al. | Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study | |
Behm et al. | Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation | |
US11590184B2 (en) | Oncolytic rhabdovirus expressing IL12 | |
DK1225870T3 (da) | Sammensætning og fremgangsmåde til cancerantigenimmunterapi | |
Alam et al. | DNA vaccines for the treatment of prostate cancer | |
WO2007016185A3 (en) | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination | |
PL1642905T3 (pl) | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy | |
Ren et al. | Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles) | |
Bashir et al. | Immunotherapy regimens for metastatic colorectal carcinomas | |
Bergman | Veterinary oncology immunotherapies | |
Lens | The role of vaccine therapy in the treatment of melanoma | |
Schütz et al. | Immunooncology in breast cancer: active and passive vaccination strategies | |
HUP0204216A2 (en) | A new use of antibodies as vaccines | |
Hrouda et al. | Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer | |
JP2002531520A5 (de) | ||
Todryk et al. | Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity | |
Anton et al. | Cytokines and tumor vaccination | |
Aurisicchio et al. | Patented cancer vaccines: the promising leads | |
Morris et al. | Therapeutic cancer vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |